Julie N. Graff, MD, discusses potential combination regimens with checkpoint inhibitors in metastatic castration-resistant prostate cancer.
Julie N. Graff, MD
Advertisement
Articles by Julie N. Graff, MD
Julie N. Graff, MD, associate professor of medicine, Oregon Health & Science University Knight Cancer Institute, discusses the phase III KEYNOTE-641 trial in metastatic castration-resistant prostate cancer (mCRPC).
Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.
Julie N. Graff, MD, discusses the results of the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.
Julie N. Graff, MD, discusses the multi-cohort, phase II KEYNOTE-199 study examining patients with metastatic castration-resistant prostate cancer.
Julie N. Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses treatment for patients with high-risk metastatic disease following the FDA approval of abiraterone acetate (Zytiga).
Advertisement
Latest Updated Articles
Dr. Graff on the Use of Abiraterone in Metastatic Prostate CancerPublished: March 3rd 2018 | Updated:
Dr. Graff on the KEYNOTE-199 Trial Design in Castration-Resistant Prostate CancerPublished: February 20th 2020 | Updated:
Dr. Graff on Results of the KEYNOTE-199 Trial in mCRPCPublished: February 27th 2020 | Updated:
Dr. Graff on the Safety of Checkpoint Inhibition in mCRPCPublished: March 18th 2020 | Updated:
Dr. Graff on the KEYNOTE-641 Trial in mCRPCPublished: March 23rd 2020 | Updated:
Dr. Graff on Combination Regimens With Checkpoint Inhibitors in mCRPCPublished: April 30th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5